Chromatography-free antibody purification method
Through the combination of filtration and precipitation steps, the problems of numerous chromatography steps and high cost in antibody purification are solved, and efficient and low-cost antibody purification is achieved, which significantly improves yield and purity.
Patent Information
- Application Number
- CN202411064281.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-08
- Filing Date
- 2019-10-08
- Publication Date
- 2024-11-22
AI Technical Summary
In the existing antibody purification methods, there are many and expensive chromatography steps, resulting in high production costs and long processing time, and it is difficult to effectively reduce the impact of impurities.
Antibody purification was performed using a method that only included filtration and precipitation steps, and high-purity antibody separation and concentration was achieved through multi-layer membrane filtration and precipitation washing processes, and the traditional chromatography steps were omitted.
The antibody production and processing costs are significantly reduced, yield and purity are improved, and the method is easy to expand, is 86% cheaper than traditional chromatography methods when scaled up, and simplifies equipment and operations.
Smart Images

Figure FT_1 
Figure BDA0004978914710000371 
Figure BDA0004978914710000372
Abstract
Description
Technical Field
[0001] The present invention relates to a method for purifying antibodies, which method comprises a limited number of steps while still allowing a high yield of purified antibodies to be obtained with excellent purity levels. In short, this method only comprises filtration and precipitation steps, while omitting the need for chromatography steps. Background Art
[0002] Antibody purification can be one of the most expensive aspects of bioproduction. Antibodies (Ab) and their fragments are typically purified using a multi-step chromatography approach, using specific resins and buffer systems in each chromatography step. This conventional purification process includes a capture step, followed by an ion exchange step, and ends with a UF / DF step. With the increase in cell culture titers and the increase in cell culture volumes to be used for production, downstream processing is seen as a bottleneck for the industry. This is particularly relevant to monoclonal antibody (mAb) production, where the focus has shifted from batch capacity to downstream processing capabilities. In addition, early preclinical and clinical stage studies require larger quantities of antibodies that can be produced more quickly. In addition, the chromatography step is one of the most important factors determining the cost of goods (CoG).
[0003] The industry has explored reducing the number of steps used for antibody purification.
[0004] WO 2011 / 090719 discloses a method for purifying an antibody comprising 2 or 3 chromatography steps, the first chromatography step involving the use of a protein A column, the second chromatography step involving the use of a cation exchange chromatography column, and the optional third chromatography step involving the use of an anion exchange chromatography column.
[0005] WO 2009 / 111347 discloses loading a multimodal resin for chromatography at a higher pH than conventionally used in the elution buffer of a Protein A column, suggesting the need to exchange the buffer between the two chromatography steps.
[0006] WO 2014 / 180852 relates to a 3-step chromatography method for small-scale and large-scale purification of proteins, in particular mAbs, using four buffer solutions prepared from mother solutions.
[0007] WO 2013 / 075740 describes an antibody purification method using only 4 buffer solutions made from mother solutions, which uses a 2-step chromatography method to purify the protein.
[0008] WO 2010 / 056550 describes a method for the purification of Nanobodies using, inter alia, 2 chromatography steps.
[0009] The widespread use of chromatography steps in antibody purification can be explained by the success of this method in the quality of the purified product, which may ultimately be used in humans. Therefore, it is preferred that any new purification method must maintain a quality that allows the final product to be used in humans.
[0010] Reducing the number of chromatography steps to only 2 drove processing time and CoG down.
[0011] However, there remains a need to optimize antibody purification, such as CoG, to further reduce antibody production and processing time, while preferably maintaining quality. Summary of the invention
[0012] The problem of purifying target proteins (such as Ab) from host cells is the huge number and size of impurities. These impurities may be larger than the target protein, smaller than the target protein, or even the same size as the target protein. This makes the purification process a challenging task, which is also solved by lengthy and expensive chromatography methods.
[0013] The inventors have discovered a new method for purifying antibodies, which includes a limited number of steps while still allowing a high yield of purified antibodies to be obtained with an excellent purity level. In short, this method only includes filtering and precipitation steps. After demonstrating its suitability in obtaining purified proteins, the inventors also show that the method can be easily expanded. The commodity cost of the purification method of the present invention is much lower than conventional chromatography methods. In fact, scaling up to 100L is 86% cheaper than comparable chromatography methods. In addition, the method can be further simplified by using a single tangential flow filtration device that only needs to replace the box and buffer. In order to further minimize CoG, the number of DV steps can be minimized while maintaining the required purity level.
[0014] In essence, the method of the present invention for purifying a protein from a solution basically comprises:
[0015] (a) a first filtration step, wherein the target protein is separated from larger impurities;
[0016] (b) a second filtration step, wherein the target protein is separated from smaller impurities;
[0017] (c) precipitation, washing and resuspension steps, wherein the protein of interest is separated from any other remaining impurities; and
[0018] (d) Ultrafiltration / diafiltration (UF / DF) step, in which the target protein is concentrated in a main buffer.
[0019] Next, the master buffer can be easily adjusted by adding excipients according to the specific needs of the purified protein, such as lyophilization, administration, etc. If desired, the resulting formulated protein can be filtered for long-term storage (optional step (e)).
[0020] In particular, the present invention relates to a method for purifying a protein from a solution, the method comprising:
[0021] (a) a first filtration step comprising: (i) passing the solution through a first membrane, thereby producing a first permeate, wherein the first membrane has a pore size of a nominal molecular weight cut-off (NMWCO) between 40 kDa and 100 kDa, preferably between 40 kDa and 80 kDa, even more preferably 50 kDa;
[0022] (b) a second filtration step, comprising: (i) concentrating the first permeate obtained at the end of step (a) using a second membrane, thereby producing a first retentate comprising said protein, wherein said second membrane has a pore size NMWCO of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa;
[0023] (c) a precipitation, washing and resuspension step, comprising: (i) precipitating the first retentate comprising the protein obtained at the end of step (b) until a precipitate comprising the protein is formed; (ii) washing the precipitate comprising the protein using a third membrane; (iii) resuspending the washed precipitate obtained at the end of step (c)(ii), thereby producing a second retentate comprising the protein; (iv) filtering the second retentate comprising the protein obtained at the end of step (c)(iii) through a third membrane, thereby producing a second permeate comprising the protein, wherein the third membrane has a pore size between 0.05-0.35 μm, such as 0.1-0.3 μm or between 0.15-0.25 μm, such as 0.2 μm;
[0024] (d) an ultrafiltration / diafiltration (UF / DF) step, comprising: (i) diafiltrating the second permeate comprising the protein obtained at the end of step (c) using a fourth membrane, thereby producing a first diafiltrate comprising the protein, wherein the fourth membrane has a pore size of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa NMWCO; (ii) concentrating the first diafiltrate comprising the protein obtained at the end of step (d)(i) using the fourth membrane, thereby producing a third retentate comprising the protein; (iii) diafiltrating the third retentate comprising the protein of step (d)(ii) using the fourth membrane, thereby producing a second diafiltrate comprising the protein;
[0025] (e) an optional formulation and final filtration step comprising: (i) formulating the second diafiltrate obtained at the end of step (d) comprising the protein in a formulation buffer, thereby producing a formulated product comprising the protein; and (ii) optionally filtering the formulated product;
[0026] Wherein the protein has a molecular weight (MW) between 5kDa-200kDa, preferably the protein has a MW between 10kDa and 150kDa, preferably between 15kDa and 100kDa, even more preferably between 15kDa and 50kDa, such as between 15kDa-30kDa, such as about 15kDa or 20kDa.
[0027] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the first filtration step (a), and / or the second filtration step (b), and / or the precipitation step (c)(i), and / or the washing step (c)(ii), and / or the resuspension step (c)(iii), and / or the filtration step (c)(iv), and / or the diafiltration step (d)(i), and / or the concentration step (d)(ii) and / or the diafiltration step (d)(iii) are carried out as tangential flow filtration (TFF) or by forward flow filtration (NFF), preferably all steps (a), (b), (c)(i), (c)(ii), (c)(iii), (c)(iv), (d)(i), (d)(ii) and (d)(iii) are carried out in the same device.
[0028] The present invention also relates to a method for purifying proteins from a solution as described herein, wherein the first membrane, and / or the second membrane, and / or the third membrane, and / or the fourth membrane comprises regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic polyether-sulfone, polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF).
[0029] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the first filtration step (a) comprises filtering with 2-4 diafiltration volumes (DV), such as 3 DV, of purified water.
[0030] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100% of said protein is recovered in said first permeate.
[0031] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the first permeate comprising the protein comprises 10%-100% less impurities than the solution, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even 80%-100% less impurities than the solution.
[0032] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein said second filtration step (b) comprises the use of purified water.
[0033] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the protein in the first retentate is concentrated to a concentration between 50-200 mg / ml, such as 75-175 mg / ml or between 100-150 mg / ml, such as about 120 mg / ml or 125 mg / ml.
[0034] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the precipitation is carried out by a precipitation solution comprising a precipitant selected from the group consisting of a miscible solvent, a nonionic hydrophilic polymer, a multivalent metal ion such as Ca 2+ Mg 2+ , Mn 2+ or Fe 2+ and neutral salts, preferably kosmotrope, most preferably (NH 4 ) + ) 2 (SO 4 ) 2- .
[0035] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the precipitation is carried out at 1.4-2.2 M, such as 1.6-2.0 M, preferably about 1.8 M ((NH 4 ) + ) 2 (SO 4 ) 2- Implemented below.
[0036] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein washing the precipitate comprising the protein in step (c)(ii) comprises replacing the precipitate solution with a washing solution, and preferably washing the precipitate with 2-8 DV, such as 4-6 DV or 5 DV of the washing solution, preferably the washing solution comprises a precipitant at a concentration between 1.4-2.2 M, such as 1.6-2.0 M, preferably about 1.8 M, preferably the precipitant is ((NH 4 ) + ) 2 (SO 4 ) 2- .
[0037] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the washed precipitate obtained at the end of step (c)(ii) is resuspended in a resuspension solution comprising a precipitant at a concentration between 0.8-0.4 M, such as 0.7-0.5 M, preferably about 0.6 M, preferably the precipitant is ((NH 4 ) + ) 2 (SO 4 ) 2- .
[0038] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the second permeate obtained at the end of step (c) comprising the protein is diafiltered with between 1-4 diafiltration volumes (DV), such as 1 DV, of the main buffer.
[0039] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the protein in the third retentate has a concentration between 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml.
[0040] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the third retentate obtained at the end of step (d)(ii) comprising the protein is diafiltered with 1-8 diafiltration volumes (DV), such as 3-6, or 4 DV or 5 DV of main buffer.
[0041] The present invention also relates to a method for purifying a protein from a solution as described herein, wherein the formulated product comprises
[0042] - protein at a concentration of 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml protein;
[0043] - a primary buffer, such as phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer, preferably the pH of the primary buffer is about 5 to about 7.5, preferably the concentration of the primary buffer is about 5 mM to about 50 mM, more preferably the primary buffer is 20 mM citrate, pH 6.0; and
[0044] -optionally from about 1% to 12% of a stabilizer selected from sucrose, sorbitol, mannitol, glycine, inositol, sodium chloride, methionine, arginine and arginine hydrochloride, preferably mannitol, preferably 10 mg / ml; and
[0045] -Optionally a surfactant at a concentration of about 0.001% to 0.6% selected from polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleate. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 : Overlay of different SE-HPLC analyses of different samples from the MIP run. DETAILED DESCRIPTION
[0047] Unless otherwise indicated or defined, all terms used have their ordinary meanings in the art, which will be clear to the skilled person. Reference is made to, for example, standard manuals, such as Sambrook et al. (Molecular Cloning: A Laboratory Manual (2nd edition) Vols. 1-3, Cold Spring Harbor Laboratory Press, 1989); F. Ausubel et al. (Current protocols in molecular biology, Green Publishing and Wiley Interscience, New York, 1987); Lewin (Genes II, John Wiley & Sons, New York, NY, 1985); Old et al. (Principles of Gene Manipulation: An Introduction to Genetic Engineering (2nd edition) University of California Press, Berkeley, CA, 1981); Roitt et al. (Immunology (6th edition) Mosby / Elsevier, Edinburgh, 2001); Roitt et al. (Roitt's Essential Immunology (10th edition) Blackwell Publishing, UK, 2001) and Janeway et al. (Immunobiology (6th edition) Garland Science Publishing, 1996). Publishing / Churchill Livingstone, New York, 2005), and the general background art cited herein.
[0048] Unless otherwise indicated, as will be clear to the skilled person, all methods, steps, techniques and operations not specifically described in detail can be carried out and have been carried out in a manner known per se. Reference is again made, for example, to the standard manuals and general background art mentioned herein, and to other references cited therein; and to reviews such as Presta (Adv. Drug Deliv. Rev. 58 (5-6): 640-56, 2006), Levin and Weiss (Mol. Biosyst. 2 (1): 49-57, 2006), Irving et al. (J. Immunol. Methods 248 (1-2): 31-45, 2001), Schmitz et al. (Placenta 21 Suppl. A: S106-12, 2000), Gonzales et al. (Tumour Biol. 26 (1): 31-43, 2005), which describe protein engineering techniques such as affinity maturation and other techniques for improving the specificity and other desired properties of proteins such as immunoglobulins.
[0049] Depending on the context, an amino acid sequence is interpreted as meaning a single amino acid or an unbranched sequence of two or more amino acids. A nucleotide sequence is interpreted as meaning an unbranched sequence of 3 or more nucleotides.
[0050] Amino acids are those L-amino acids commonly found in naturally occurring proteins. Amino acid residues will be indicated according to the standard three-letter or single-letter amino acid code. Reference is made to Table A-2 on page 48 of WO 08 / 020079, for example. Those amino acid sequences containing D-amino acids are not intended to be encompassed by this definition. Any amino acid sequence containing post-translationally modified amino acids can be described as the originally translated amino acid sequence using the symbols and modification positions shown in this Table A-2; for example, hydroxylation or glycosylation, but these modifications should not be explicitly shown in the amino acid sequence. Any peptide or protein that can be represented as a sequence-modified connection, cross-linking and end cap, non-peptidyl bond, etc. is encompassed by this definition.
[0051] Unless otherwise stated, the terms "approximately," "about," or "substantially" in connection with a numerical value mean within a range of ±10% of the stated value.
[0052] The filtering step as described herein can be performed by any suitable mechanical, physical or biological manipulation to purify (e.g. separate) the target protein from impurities. Preferably, the filtering step is performed using a semipermeable membrane. The filtering can be performed using one or more devices in which a feed solution containing the protein is contacted with a device that flows in parallel or in series.
[0053] As used herein, "semipermeable membrane" refers to any type of biological or synthetic polymer membrane, which contains holes that allow certain molecules or ions to pass through it by diffusion, facilitated diffusion, passive transport or active transport while retaining other molecules. The rate of passage depends on the pressure, concentration and temperature of the molecules or solutes on both sides, and the permeability of the membrane to each solute. Depending on the membrane and the solute, the permeability may depend on the size, solubility, characteristics and chemical properties of the solute. The terms "semipermeable membrane" and "membrane" are used interchangeably throughout this disclosure, and for the purposes of this disclosure, each has the same meaning. Depending on the pore size of the membrane, it is possible to distinguish between membranes for microfiltration and ultrafiltration. The membrane used for microfiltration generally has a pore size between 0.1 μm and 10 μm. The membrane used for ultrafiltration generally has a pore size (e.g., 10kD and 50kD membrane) lower than 0.1 μm.
[0054] In some embodiments, for example in the first filtration step (a), the membrane has a pore size of nominal molecular weight cut-off (NMWCO) between 40 kDa and 100 kDa, preferably between 40 kDa and 80 kDa, even more preferably 50 kDa.
[0055] In some embodiments, e.g. in the second filtration step (b) or the UF / DF step (d), the membrane has a pore size NMWCO of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa.
[0056] In embodiments, for example in the precipitation, washing and resuspension step (c), the membrane has a pore size between 0.05-0.35 μm, such as 0.1-0.3 μm, or between 0.15-0.25 μm, such as 0.2 μm.
[0057] Representative suitable membranes that can be used in the methods of the present invention include those formed from regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic polyether-sulfone, polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF), etc. These membranes can be provided, for example, in cartridge form (e.g., NFF) or as cassettes (e.g., for TFF). In certain embodiments, the membrane is a Satorius Membrane, Sartorius Q membrane or Sartorius membrane.
[0058] As used herein, "ultrafiltration" or "UF" refers to a filtration technique using a semipermeable membrane to physically and selectively remove particles and / or ions from a solution based on the particle size and the size of the pores in the UF membrane. Typically, the semipermeable membrane has very small (0.001 μm to 0.1 μm) pores to sort or concentrate molecules in a feed stream using a pressure differential across the membrane. UF membranes are sometimes classified based on molecular weight cutoff (MWCO) rather than pore size.
[0059] Ultrafiltration can also be used to concentrate the target protein. Concentration via UF is a simple process that involves removing fluid from solution while retaining solute molecules. The concentration of the solute increases in direct proportion to the reduction in the volume of the solution, i.e., halving the volume effectively doubles the concentration. In order to concentrate the sample, an ultrafiltration membrane with a MWCO much lower than the molecular weight of the protein to be retained is selected, which ensures retention and high recovery of the target protein (see second filtration step (b) and UF / DF step (d) of the present invention).
[0060] Ultrafiltration can also be used to purify smaller molecules (such as the protein of interest) from larger impurities (such as host cells and process-related impurities) that cannot pass through the membrane (see the first filtration step (a) of the present invention).
[0061] The molecular weight cutoff (MWCO) of a membrane (sometimes referred to as the nominal molecular weight limit (NMWL) or nominal molecular weight cutoff (NMWCO)) is defined by its ability to retain a given percentage of a spherical solute with a defined molecular weight. Solute retention varies due to molecular shape, structure, solute concentration, the presence of other solutes, and ionic conditions. Therefore, it will be appreciated by those skilled in the art that the MWCO rating is based on spherical molecules, while more linear molecules (which may have a small diameter in two of the three dimensions) may be able to pass more freely through the hole, despite having a molecular weight exceeding the MWCO. In order to ensure the correct retention of the target protein, those skilled in the art can select a membrane with the desired properties by performing some routine experiments. A good general rule is to select a membrane whose MWCO is 1 / 3 to 1 / 6 of the molecular weight of the target protein to be retained.
[0062] Traditionally, the MWCO of a membrane refers to the minimum average molecular weight of a standard molecule that will not diffuse effectively across the membrane. As used herein, "molecular weight cutoff" or "MWCO" refers to the molecular weight of the lowest molecular weight solute (in Daltons) retained by 90% of the solutes or the molecule (e.g., globular protein) retained by 90% of the membrane. Preferred UF membranes have a nominal MWCO rating of 2kDa, 3.5kDa, 5kDa, 7kDa, 10kDa, 15kDa, and 20kDa, even more preferably 10kDa. For example, UF is used in steps (b) and (d) of the present invention.
[0063] As used herein, during the "concentration" portion, the initial volume V 0 Concentrate to a final retentate volume ("V"), so the volume concentration factor (VCF) can be defined as VCF = V 0 / V. During (dia)filtration, the diavolume (DV) is a measure of the extent of buffer exchange that has taken place during the (dia)filtration step. If a constant volume (dia)filtration is to be performed, in which the retentate volume (V) is kept constant and the (dia)filtration volume V D Entering at the same rate as the filtrate leaves, DV is calculated as DV = V D Other operating parameters that may affect step performance include filter design (such as channel size and shape) and materials and construction, all of which are known to those skilled in the art and all of which are assessed on a routine basis, such as during screening for suitable membranes.
[0064] As used herein, "transmembrane pressure" or "TMP" refers to the driving force for transporting a liquid through a membrane. It is calculated as the average pressure exerted on the membrane minus any filtrate pressure. In most cases, the pressure at the filtrate port is equal to zero.
[0065] As used herein, "diafiltration" or "DF" refers to a technique using a semipermeable membrane that separates larger molecules that cannot pass through the membrane (the retentate) from smaller molecules that can pass through the membrane (the permeate). DF washes smaller molecules through the semipermeable membrane (the permeate) and leaves larger molecules in the retentate. DF can be used to completely remove, replace, or reduce the concentration of salts or solvents from a solution (see steps (a), (c), and (d) of the present invention). DF can be performed continuously or discontinuously.
[0066] In continuous diafiltration, DF solution is added to the sample feed reservoir at the same rate as the filtrate is produced. The result is that smaller molecules that permeate the membrane are washed out while the volume in the sample reservoir remains constant.
[0067] In discontinuous diafiltration, the DF solution is first diluted to increase the initial volume and then concentrated as the filtrate is produced. The process is then repeated until the desired concentration of small molecules remaining in the sample pool is reached.
[0068] Discontinuous diafiltration requires more filtrate volume to achieve the same degree or reduction of small molecule permeates as continuous diafiltration.
[0069] The DF process sometimes uses a diafiltration volume, which refers to the volume of the solution before the DF solution is added. Each additional diafiltration volume (DV) will further reduce the salt concentration. Typically, using 5 diafiltration volumes will reduce the ionic strength by about 99% in the case of continuous diafiltration.
[0070] As used herein, the term "retentate" in connection with filtration refers to a solution retained on the retentate side of the membrane and containing molecules that are too large to pass through the membrane, such as impurities in step (a) of the present invention or target proteins in step (b) of the present invention.
[0071] For the sake of brevity, the acronyms "UF", "DF" and "UF / DF" (or "UFDF") may be used throughout the description and should be understood as follows: "UF" means "ultrafiltration", "DF" means "diafiltration", and "UF / DF" (or "UFDF") means "ultrafiltration / diafiltration".
[0072] "Tangential flow filtration" ("TFF") or "cross-flow filtration" refers to filtration in which the feed stream is passed parallel to the membrane face, with a portion passing through the membrane (permeate) and the remainder (retentate) being recycled back to the feed reservoir. It is often used instead of "forward flow filtration" ("NFF"), in which the feed stream is applied perpendicular to the membrane. TFF is preferred because NFF may result in compression of the mixture at the membrane, resulting in inadequate separation.
[0073] As used herein, "filtrate" (also sometimes denoted herein as "permeate") is the sample that has passed through a membrane.
[0074] As used herein, "recovery" relates to the amount (amount, quality or activity) of protein recovered after processing (e.g., after filtration) compared to the amount in the starting sample (e.g., before filtration). Recovery is generally expressed herein as a percentage of the starting material.
[0075] The inventors have demonstrated the scalability of the method of the present invention by using 2L, 10L, 100L and even 2000L of starting material (see Examples). It will be appreciated by those skilled in the art that the method of the present invention can be further scaled up or scaled down as needed. As used herein, "membrane loading" is defined as the amount of the target protein loaded on the filtration step divided by the area of the filter (membrane). This parameter can be used for scaled up and scaled down of the filtration step so that the scaling method involves keeping the membrane loading the same.
[0076] The present invention uses precipitation and washing steps to further reduce contaminants (see step (c) of the present invention).
[0077] The person skilled in the art is familiar with the basic mechanism of precipitation, which is to change the solvation potential of the solvent, more specifically to reduce the solubility of the solute (ie the protein of interest) by adding a precipitant.
[0078] Typically, the formation of protein precipitates ("precipitation") occurs in a stepwise process. First, a precipitation solution containing a precipitating agent ("precipitant") is added and the solution is stably mixed. Mixing causes the precipitating agent and protein to collide. Next, the protein undergoes a nucleation phase, during which submicroscopic protein aggregates or particles are produced. During the final step, the protein precipitate particles repeatedly collide and stick, then break apart until a stable average protein particle size is reached ("aging"). The mechanical strength of the protein particles is related to the product of the average shear rate and the aging time, which is called the Camp number. Aging helps the insoluble solid protein particles (precipitate) withstand the fluid shear forces encountered in the pump and centrifuge feed zone without reducing in size.
[0079] As used herein, "precipitate" refers to an insoluble solid containing a target protein. The precipitate may appear as a suspension. As used herein, "precipitant" refers to any chemical that causes a solid to form in a liquid solution.
[0080] Any suitable precipitation method can be used in the method of the present invention, such as isoelectric precipitation, precipitation with a miscible solvent, precipitation via a non-ionic hydrophilic polymer, precipitation via a polyvalent metal ion (such as Ca 2+ Mg 2+ , Mn 2+ or Fe 2+ ) and precipitation by salting out, preferably by salting out.
[0081] The proteins of the present invention can be precipitated by salt-induced precipitation ("salting out"), which is the most common method used to precipitate proteins. Adding neutral salts compresses the solvation layer and increases protein-protein interactions. As the salt concentration of the solution increases, the charges on the surface of the protein interact with the salt instead of water, exposing hydrophobic patches on the surface of the protein and causing the protein to fall out of solution (aggregate and precipitate). Preferred neutral salts are hydrotropes or "water structure stabilizers" that promote the dissipation / dispersion of water from the solvation layer around the protein. Preferred neutral salts are (PO 4 ) 3- 、(SO 4 ) 2- 、SOO - and Cl - With (NH 4 ) + , K + and Na + The most preferred salt is ((NH 4 ) + ) 2 (SO 4 ) 2- .
[0082] The proteins of the present invention can also be precipitated by isoelectric precipitation, for example with trichloroacetic acid. For example, precipitation can be achieved by changing the pH of the medium. At low pH, proteins have a net positive charge because the amides have gained additional protons. At high pH, they have a net negative charge because the carboxyl groups on the protein backbone have lost their protons. At their pI values, the proteins have no net charge. This results in reduced solubility because the protein cannot interact with the medium and will then fall out of solution. Trichloroacetic acid (TCA) is often used for precipitation because it sees good results at relatively low concentrations (usually about 15%). Organic solvents (such as acetone) can also be used for protein precipitation, usually in combination with TCA. Organic solvents reduce the dielectric constant of the organic solvent, resulting in a loss of solubility and therefore precipitation.
[0083] In order to further reduce the amount of impurities, the precipitate can be washed with a "washing solution". In order to maximize the yield, this washing step requires that the precipitate remains precipitated, for example, the precipitate is not or only substantially not resuspended. On the other hand, it is preferred that the washing step does not gather other compounds, such as impurities. Those skilled in the art will be able to select appropriate washing solutions for this washing step, including assessments such as ionic strength, molar concentration, etc. Preferred washing solutions are the same or similar to the solution used for precipitation, such as solutions comprising miscible solvents, nonionic hydrophilic polymers, multivalent metal ions or neutral salts, preferably neutral salts.
[0084] Preferably, the washing solution comprises a neutral salt, more preferably (NH 4 ) + ) 2 (SO 4 ) 2- .
[0085] In order to further manipulate the target protein, it is preferred to dissolve the protein or bring the protein into solution. As used herein, "resuspending" means dissolving the solute (i.e., the target protein) in a solvent (i.e., a resuspension solution). The resulting solution contains the resuspended product. Again, those skilled in the art are fully aware of suitable resuspension solutions and how to use them. For example, the precipitated protein can be dissolved by reducing the concentration of the washing solution used in the washing step by adding purified water. In a preferred embodiment, the neutral salt (e.g., (NH 4 ) + ) 2 (SO 4 ) 2- ) is reduced to about 0.4M to about 0.8M, preferably to about 0.6M.
[0086] The terms "protein", "peptide", "protein / peptide" and "polypeptide" are used interchangeably throughout this disclosure and, for the purposes of this disclosure, each has the same meaning. Each term refers to an organic compound composed of a linear chain of two or more amino acids. The compound may have ten or more amino acids; twenty-five or more amino acids; fifty or more amino acids; one hundred or more amino acids; two hundred or more amino acids; or even three hundred or more amino acids. The skilled artisan will appreciate that polypeptides generally contain fewer amino acids than proteins, although there is no art-recognized demarcation point for the number of amino acids that distinguishes polypeptides from proteins; polypeptides may be prepared by chemical synthesis or recombinant methods; and proteins are generally prepared in vitro or in vivo by recombinant methods known in the art. The term "protein" as used herein refers to a molecule having the sequence of a natural protein (i.e., a protein produced by a naturally occurring, particularly non-recombinant cell or a genetically engineered or recombinant cell), and includes molecules having an amino acid sequence of a natural protein or molecule with one or more amino acids of the natural sequence deleted, added and / or substituted. In certain aspects, the protein to be purified is an antibody. As contemplated herein, the term "protein" includes "polypeptides," "immunoglobulins," "antibodies," and "antibody fragments."
[0087] Unless otherwise indicated, the terms "immunoglobulin" and "immunoglobulin sequence" (whether used herein to refer to heavy chain antibodies or to conventional four-chain antibodies) are used as broad terms to include both full-sized antibodies, individual chains thereof, and all parts, domains or fragments thereof (including but not limited to antigen binding domains or fragments, such as V and V, respectively). HH Domain or V H / V L domain).
[0088] As used herein, the term "antibody" refers to an intact antibody or a binding fragment thereof that competes with an intact antibody for specific binding. Binding fragments include, but are not limited to, F(ab), F(ab'), F(ab')2, Fv, and single-chain antibodies.
[0089] As used herein, the term "domain" (of a polypeptide or protein) refers to a folded protein structure that has the ability to maintain its tertiary structure independently of the rest of the protein. Typically, domains are responsible for discrete functional properties of a protein and in many cases can be added, removed, or transferred to other proteins without loss of function of the rest of the protein and / or the domain.
[0090] The term "immunoglobulin domain" as used herein refers to a globular region of an antibody chain (e.g., such as a chain of a conventional 4-chain antibody or a heavy chain antibody), or to a polypeptide consisting essentially of such a globular region. Immunoglobulin domains are characterized in that they retain the immunoglobulin fold characteristic of antibody molecules, consisting of a double-layer sandwich of about seven antiparallel β chains arranged in two β folds, optionally stabilized by conserved disulfide bonds.
[0091] As used herein, the term "immunoglobulin variable domain" means an immunoglobulin domain that is essentially composed of four "framework regions", which are referred to in the art and hereinafter as "framework region 1" or "FR1", "framework region 2" or "FR2", "framework region 3" or "FR3" and "framework region 4" or "FR4", respectively; the framework regions are interrupted by three "complementarity determining regions" or "CDRs", which are referred to in the art and hereinafter as "complementarity determining region 1" or "CDR1", "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3". Thus, the general structure or sequence of an immunoglobulin variable domain can be indicated as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. One or more ISVDs confer specificity to an antibody for an antigen by carrying an antigen binding site, in particular CDR1, CDR2 and / or CDR3.
[0092] The term "immunoglobulin single variable domain" ("ISV" or "ISVD"), which is used interchangeably with "single variable domain", defines a molecule in which the antigen binding site is present on and formed by a single immunoglobulin domain. This distinguishes ISVs from "conventional" immunoglobulins or fragments thereof, in which two immunoglobulin domains, in particular two variable domains, interact to form an antigen binding site. Typically, in conventional immunoglobulins, the heavy chain variable domain (VH) and the light chain variable domain (VL) interact to form an antigen binding site. In this case, the complementarity determining regions (CDRs) of both VH and VL will contribute to the antigen binding site, i.e. a total of 6 CDRs will participate in the formation of the antigen binding site.
[0093] In view of the above definition, conventional 4-chain antibodies (such as IgG, IgM, IgA, IgD or IgE molecules; known in the art) or antigen binding domains derived from such conventional 4-chain antibodies, Fab fragments, F(ab')2 fragments, Fv fragments (such as disulfide-linked Fv or scFv fragments) or diabodies (all known in the art) will generally not be regarded as ISVs, because in these cases, binding to the corresponding epitope of the antigen generally does not occur through one (single) immunoglobulin domain, but rather through a pair of (associated) immunoglobulin domains (such as light chain and heavy chain variable domains) that bind together to the epitope of the corresponding antigen, i.e., through a VH-VL pair of immunoglobulin domains.
[0094] In contrast, ISVs are able to specifically bind to an epitope of an antigen without pairing with an additional immunoglobulin variable domain. The binding site of an ISV is formed by a single VH, a single VHH, or a single VL domain. Thus, the antigen binding site of an ISV is formed by no more than three CDRs.
[0095] Therefore, the single variable domain can be a light chain variable domain sequence (e.g., a VL sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g., a VH sequence or a VHH sequence) or a suitable fragment thereof; as long as it is able to form a single antigen binding unit (i.e., a functional antigen binding unit substantially consisting of a single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit).
[0096] In one embodiment of the present invention, the ISV is a heavy chain variable domain sequence (e.g., a VH sequence); more particularly, the ISV may be a heavy chain variable domain sequence derived from a conventional four-chain antibody or a heavy chain variable domain sequence derived from a heavy chain antibody.
[0097] For example, the ISV may be a (single) domain antibody, an amino acid suitable for use as a (single) domain antibody, an immunoglobulin suitable for use as a (single) domain antibody, a "dAb" or dAb, or an amino acid suitable for use as a dAb, or a Nanobody (as defined herein, and including but not limited to VHH), a humanized VHH sequence, a camelized VH sequence, a VHH sequence that has been obtained by affinity maturation, other single variable domains, an immunoglobulin single heavy chain variable domain, or any suitable fragment of any of them.
[0098] In particular, the ISV may be (as defined herein) or a suitable fragment thereof. [Note: and is a registered trademark of Ablynx NV.] For a general description of Nanobodies, reference is made to the further description below, and to the prior art cited herein, as for example described in WO 08 / 020079 (page 16).
[0099] "VHH domain" (also known as VHH, V H H domains, VHH antibody fragments, and VHH antibodies) were originally described as “heavy chain antibodies” (i.e., “antibodies without light chains”; Hamers-Casterman et al. Nature 363:446-448, 1993) antigen-binding immunoglobulin (variable) domains. The term “VHH domain” has been chosen to distinguish these variable domains from the heavy chain variable domains present in conventional 4-chain antibodies (which are referred to herein as “V H domain” or “VH domain”) and the light chain variable domain present in conventional 4-chain antibodies (which are referred to herein as “V L For further description of VHH and Nanobodies, reference is made to, for example, the review article by Muyldermans (Reviews in Molecular Biotechnology 74: 277-302, 2001) and WO 04 / 041867, WO 04 / 041862, WO 04 / 041865, WO 04 / 041863, WO 04 / 062551, WO 05 / 044858, WO 06 / 40153, WO 06 / 079372, WO 06 / 122786, WO 06 / 122787 and WO 06 / 122825 of Ablynx NV and Ablynx Other disclosed patent applications of NV. Reference is also made to other prior art mentioned in these applications, in particular to the list of references mentioned on pages 41-43 of international application WO06 / 040153, which are incorporated herein by reference. As described in these references, the features of ISVs, nanobodies (particularly VHH sequences and partially humanized nanobodies) can be particularly characterized by the presence of one or more "hallmark residues" in one or more framework sequences. Further descriptions of ISVs, nanobodies (including humanization and / or camelization of nanobodies), and other modifiers, parts or fragments, derivatives or "nanobody fusions", multivalent constructs (including some non-limiting examples of linker sequences) and different modifiers that increase the half-life of ISVs, nanobodies and their preparations can be found, for example, in WO 08 / 101985 and WO 08 / 142164. For a further general description of nanobodies, reference is made to the prior art cited herein, for example as described in WO 08 / 020079 (page 16).
[0100] "Domain antibodies" (also known as "Dabs", "Domain Antibodies" and "dAbs") (the terms "Domain Antibodies" and "dAbs" are used as trademarks by GlaxoSmithKline plc) have been described in, for example, EP 0368684, Ward et al. (Nature 341:544-546, 1989), Holt et al. (Tends in Biotechnology 21:484-490, 2003) and WO 03 / 002609 and in, for example, WO 04 / 068820, WO 06 / 030220, WO 06 / 003388 and other published patent applications of Domantis Ltd. Domain antibodies correspond essentially to the VH or VL domains of non-Camelid mammals, in particular humans, 4-chain antibodies. In order to bind an epitope as a single antigen binding domain, i.e. without pairing with a VL or VH domain, respectively, specific selection for such antigen binding properties is required, e.g. by using a library of human single VH or VL domain sequences. Domain antibodies (like VHH) have a molecular weight of about 13 to about 16 kDa and, if derived from fully human sequences, do not require humanization for therapeutic use, e.g. in humans.
[0101] For example, but not limitation, one or more ISVs may be used as a "binding unit," "binding domain," or "building block" (these terms are used interchangeably) to prepare a polypeptide, which may optionally contain one or more additional ISVs that may serve as binding units (i.e., to the same or another epitope and / or to one or more other antigens, proteins, or targets).
[0102] A method for preparing a multivalent polypeptide comprising more than one ISV may comprise at least the steps of linking together two or more ISVs of the invention and, for example, one or more linkers in a suitable manner. The ISVs of the invention (and linkers) may be coupled by any method known in the art and as further described herein. A preferred technique comprises linking nucleic acid sequences encoding the ISVs of the invention (and linkers) to prepare a genetic construct expressing the multivalent polypeptide. Techniques for linking amino acids or nucleic acids will be clear to the skilled person and reference is again made to the standard manuals mentioned above (such as Sambrook et al. and Ausubel et al.) and to the examples below.
[0103] In a preferred embodiment, the protein of interest is a polypeptide comprising one or more (such as 2 or 3) VHHs.
[0104] The protein of interest may be expressed and secreted in any suitable host cell. Suitable hosts or host cells will be clear to the skilled person and may for example be any suitable fungal, prokaryotic or eukaryotic cell or cell line or any suitable fungal, prokaryotic or (non-human) eukaryotic organism, for example:
[0105] - bacterial strains, including but not limited to Gram-negative strains, such as Escherichia coli; Proteus, such as Proteus mirabilis; Pseudomonas, such as strains of Pseudomonas fluorescens; and Gram-positive strains, such as Bacillus, such as Bacillus subtilis or Bacillus brevis; Streptomyces, such as Streptomyces lividans; Staphylococcus, such as Staphylococcus carnosus; and Lactococcus, such as strains of Lactococcus lactis;
[0106] - fungal cells, including but not limited to cells from Trichoderma species, such as from Trichoderma reesei; Neurospora species, such as from Neurosporacrassa; Sordaria species, such as from Sordaria macrospora; Aspergillus species, such as from Aspergillus niger or from Aspergillus sojae; or cells from other filamentous fungi;
[0107] yeast cells, including but not limited to cells from the following species: Saccharomyces, such as Saccharomyces cerevisiae; Schizosaccharomyces, such as Schizosaccharomyces pombe; Pichia, such as Pichia pastoris or Pichia methanolica; Hansenula, such as Hansenula polymorpha; Kluyveromyces, such as Kluyveromyces lactis; Arxula, such as Arxula adeninivorans; Yarrowia, such as Yarrowia lipolytica;
[0108] - amphibian cells or cell lines, such as Xenopus oocytes;
[0109] - cells or cell lines of insect origin, such as cells / cell lines derived from the order Lepidoptera, including but not limited to Spodoptera SF9 and Sf21 cells or cells / cell lines derived from Drosophila, such as Schneider and Kc cells;
[0110] - plants or plant cells, such as tobacco plants; and / or
[0111] - mammalian cells or cell lines, such as cells or cell lines derived from humans, cells or cell lines derived from mammals, including but not limited to CHO cells (e.g. CHO-K1 cells), BHK cells and human cells or cell lines, such as HeLa, COS, Caki and HEK293H cells;
[0112] As well as all other host cells or (non-human) hosts known per se for the expression and production of antibodies and antibody fragments (including but not limited to (single) domain antibodies and ScFv fragments), which will be clear to the skilled person. Reference is also made to the general background art cited above and to, for example, WO 94 / 29457; WO 96 / 34103; WO 99 / 42077; Frenken et al. (Res Immunol. 149: 589-99, 1998); Riechmann and Muyldermans (1999), supra; van der Linden (J. Biotechnol. 80: 261-70, 2000); Joosten et al. (Microb. Cell Fact. 2: 1, 2003); Joosten et al. (Appl. Microbiol. Biotechnol. 66: 384-92, 2005); and to the other references cited therein.
[0113] In order to produce / obtain expression of a protein of the invention, the host cell or host organism may generally be maintained, maintained and / or cultured under conditions such that the (desired) polypeptide of the invention is expressed / produced. Suitable conditions will be clear to the skilled person and will generally depend on the host cell / host organism used, and the regulatory elements controlling expression of the protein of the invention.
[0114] The method of the present invention for purifying a protein from a solution relies on various filtration steps, wherein in particular the protein of interest is separated from larger impurities (step (a) of the method), and the protein of interest is separated from smaller impurities; (step (b) of the method). Those skilled in the art will appreciate that the nominal size of the protein may require adjustment of the MWCO of the membranes used in the various steps. For example, an intact IgG antibody of approximately 150 kDa in size may require different first and second membranes that are 1 / 10 the size of a VHH. Given the teachings of the present invention, those skilled in the art may instantly adjust the pore size of the membrane according to the protein of interest.
[0115] Preferably, the protein of interest is less than 50 kDa, such as a polypeptide comprising 1, 2 or 3 VHHs of a size of about 13-16 kDa, 26-32 kDa or 39-48 kDa, respectively, even more preferably a polypeptide comprising 1 VHH of a size of up to about 20 kDa, more preferably about 13-16 kDa.
[0116] The methods disclosed herein are intended to purify proteins from solutions. As used herein, "purified" and "to purify" refer to the final purity that allows the effective use of proteins in vitro, in vitro or in vivo. In order for a protein to be useful in an in vitro, in vitro or in vivo application, it should be substantially free of impurities, such as contaminants, other proteins, host cells, product-related variants and / or chemicals, which may interfere with the use of the protein in such applications, or at least do not wish to be included with the target protein. Such applications include preparing therapeutic compositions, administering proteins in therapeutic compositions, and other methods disclosed herein. Preferably, a "purified" protein as referred to herein is a protein that has been purified from impurities or other protein components such that the protein of interest comprises at least about 80% weight / weight of the total protein in a given composition, and more preferably, at least about 85%, more preferably at least about 90%, more preferably at least about 91%, more preferably at least about 92%, more preferably at least about 93%, more preferably at least about 94%, more preferably at least about 95%, more preferably at least about 96%, more preferably at least about 97%, more preferably at least about 98%, more preferably at least about 99% weight / weight of the total protein in a given composition.
[0117] The target protein and the contaminating proteins that may be present in the sample can be monitored by any appropriate means.Therefore, purity can be determined by conventional methods known in the art or described in the Examples section, such as electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of the method for assessing protein purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007). Preferably, the technology should be sensitive enough to detect pollutants in the range of about 2 millionths (ppm) (calculated as nanograms of protein to be purified per milligram) and 500ppm. For example, enzyme-linked immunosorbent assay (ELISA) (a method well known in the art) can be used to detect the contamination of the protein by the second protein. See, e.g., Reen (1994), Enzyme-Linked Immunosorbent Assay (ELISA), in Basic Protein and Peptide Protocols, Methods MoI. Biol. 32: 461-466, which is incorporated herein by reference in its entirety. In one aspect, following the methods described herein, contamination of the protein by such other proteins can be reduced, preferably by at least about two-fold, more preferably by at least about three-fold, more preferably by at least about five-fold, more preferably by at least about ten-fold, more preferably by at least about twenty-fold, more preferably by at least about thirty-fold, more preferably by at least about forty-fold, more preferably by at least about fifty-fold, more preferably by at least about sixty-fold, more preferably by at least about seventy-fold, more preferably by at least about 80-fold, more preferably by at least about 90-fold, and most preferably by at least about 100-fold.
[0118] In another aspect, after the method described herein, the contamination of the protein by such other proteins is no more than about 10,000ppm, preferably no more than about 2500ppm, more preferably no more than about 400ppm, more preferably no more than about 360ppm, more preferably no more than about 320ppm, more preferably no more than about 280ppm, more preferably no more than about 250ppm. The range of such contamination can be from an undetectable level to about 10ppm or from about 10ppm to about 10,000ppm. If the target protein is to be purified for pharmacological purposes, those skilled in the art will appreciate that the preferred level of the second contaminating protein can depend on the weekly dose of the target protein to be administered to each patient, with the purpose that the contaminated protein received by the patient each week will not exceed a certain amount.
[0119] The amount of DNA that may be present in the protein sample to be purified can be determined by any suitable method. For example, an assay utilizing polymerase chain reaction can be used (see Examples section). Optionally, the technique can detect DNA contamination at levels of 10 pg / mg protein and higher. The DNA level can be reduced by HIC (hydrophobic interaction chromatography), optionally by about two times, preferably by about five times, more preferably by about ten times, more preferably by about fifteen times, most preferably by about 20 times. Optionally, the DNA level after HIC (such as hydroxyapatite chromatography) is less than about 20 pg / mg protein, preferably less than 15 pg / mg protein, more preferably less than 10 pg / mg protein, and most preferably less than 5 pg / mg protein.
[0120] The term "protein formulation" (also indicated herein as "formulation") refers to a final product comprising a target protein, a primary buffer, and optional excipients. When referring to a protein intended for therapeutic use, the term "drug substance" may be used instead of "protein formulation", and the target protein may be represented by the terms "active ingredient" or "product". As used herein, a "primary buffer" is any buffer suitable for further processing or use, whether or not excipients are added. Typically, the primary buffer has a pH of 5.0 to 7.5 and is suitable for administration. "Excipients" are defined by all ingredients of a "protein formulation" that are not "proteins" or "active ingredients". Excipients typically include lyoprotectants; surfactants; fillers; tonicity regulators; stabilizers; and preservatives.
[0121] In preferred embodiments, the main buffer includes but is not limited to phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer and / or citrate buffer, preferably citrate buffer. Acceptable salts may include but are not limited to sodium chloride, ammonium chloride, potassium chloride, sodium acetate, ammonium acetate, sodium sulfate, ammonium sulfate, ammonium thiocyanate, sodium citrate, sodium phosphate and potassium, magnesium and calcium salts thereof, and combinations of these salts. The concentration of the phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer and / or citrate buffer is about 5mM to about 50mM, about 5mM to about 40mM, about 5mM to about 30mM, about 10mM to about 20mM, or about 10mM, about 20mM or about 30mM. In other embodiments, the buffer in the formulation is a Tris buffer present at a concentration of less than about 5 mM to about 50 mM, about 5 mM to about 40 mM, about 5 mM to about 30 mM, about 10 mM to about 20 mM, or about 10 mM, about 20 mM, or about 30 mM. The pH of the buffer of the formulation is generally between about 5 and 7. In some specific embodiments, the pH of the buffer of the formulation is about 5 to about 7.5, about 5.5 to about 7.2. For example, the pH of the buffer can be about 5, 5.5, 5.8-6.1, 6, 6.1, 6.5, or 7. Preferably, the primary buffer is 20 mM citrate buffer pH 6.0.
[0122] In certain embodiments, the concentration of the protein (e.g., Nanobody or polypeptide comprising 1, 2 or 3 VHHs) in the "protein formulation" is about 0.5 mg / mL to about 350 mg / mL, about 0.5 mg / mL to about 300 mg / mL, about 0.5 mg / mL to about 250 mg / mL, about 0.5 mg / mL to about 150 mg / mL, about 1 mg / ml to about 130 mg / mL, about 10 mg / ml to about 130 mg / mL, about 50 mg / ml to about 120 mg / mL, about 80 mg / ml to about 120 mg / mL, about 88 mg / ml to about 100 mg / mL or about 10 mg / ml, about 25 mg / ml, about 50 mg / ml, about 80 mg / ml, about 100 mg / mL, about 130 mg / ml, about 150 mg / ml, about 200 mg / ml, about 250 mg / ml or about 300 mg / ml.
[0123] In other embodiments, the lyoprotectant of the formulation is a sugar, such as sucrose, sorbitol or trehalose. For example, the lyoprotectant can be sucrose, sorbitol or trehalose at a concentration of about 2.5% to about 10%, about 5% to about 10%, about 5% to about 8%, or about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5% or about 9% (weight / volume).
[0124] In some embodiments, the formulation includes a surfactant at a concentration of about 0.001% to 0.6% (e.g., about 0.01% to 0.6%, about 0.1% to 0.6%, about 0.1% to 0.5%, about 0.1% to 0.4%, about 0.1% to 0.3%, about 0.1% to 0.2%, or about 0.01% to 0.02%). In some cases, the formulation contains greater than 0% and up to about 0.6% (e.g., about 0.1% to 0.2%) of polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleate, or a combination thereof. In specific embodiments, the formulation contains about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01% to 0.02%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.1% to 0.2%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, or 0.2% polysorbate-80. Alternatively, the formulation may include about 0.01% to 0.6%, about 0.1% to 0.6%, about 0.1% to 0.5%, about 0.1% to 0.4%, about 0.1% to 0.3%, or about 0.1% to 0.2% of poloxamer-188.
[0125] In certain embodiments, the formulation includes a bulking agent, such as glycine, at a concentration of from about 10 to about 200 mM, from about 25 to about 175 mM, from about 50 to about 150 mM, from about 75 to about 125 mM, or about 100 mM.
[0126] In other embodiments, the formulation further comprises a tonicity adjusting agent, such as a molecule that makes the formulation substantially isotonic or isotonic with human blood. Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine, and arginine hydrochloride.
[0127] In yet other embodiments, the formulation further includes a stabilizer, such as a molecule that greatly prevents or reduces the chemical and / or physical instability of the target protein in a lyophilized, liquid or stored form when combined with the target protein. Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride. In certain embodiments, the formulation includes one or more of the following ranges of stabilizers: from about 1% to about 12% (e.g., about 5%, about 7.5%, about 8%, or about 10%) of sucrose; from about 1% to about 7% (e.g., about 3%, about 4%, about 5%) of sorbitol; from about 1% to about 5% of inositol; from about 10mM to about 125mM (e.g., about 25mM to 100mM, about 80mM, about 90mM, or about 100mM) of glycine; from about Sodium chloride from about 10 mM to 150 mM (e.g., about 25 mM to 100 mM, about 55 mM); methionine from about 10 mM to about 100 mM (e.g., about 10 mM, about 20 mM, about 100 mM); arginine from about 10 mM to about 125 mM (e.g., about 25 mM to about 120 mM or about 100 mM); arginine hydrochloride from about 10 mM to about 70 mM (e.g., about 10 mM to about 65 mM or about 55 mM).
[0128] In other embodiments, the formulation may also include methionine at a concentration of from about 10 to about 200 mM, from about 25 to about 175 mM, from about 50 to about 150 mM, from about 75 to about 125 mM, or about 100 mM.
[0129] In one embodiment, the components of the formulation can act as one or more of a lyoprotectant, a tension regulator and / or a stabilizer. For example, depending on the concentration of a component (e.g., sucrose), it can act as one or more of a lyoprotectant, a tension regulator and / or a stabilizer. In other embodiments, where several components are needed in the formulation, different components are used. For example, where the formulation requires a lyoprotectant, a tension regulator and a stabilizer, different components are used (e.g., sucrose, glycine and inositol can be used in combination to produce a combination of a lyoprotectant, a tension regulator and a stabilizer, respectively).
[0130] Preferably, the protein formulation is stable. A "stable" formulation is a formulation in which the protein substantially maintains its physical and chemical stability and integrity during storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature within a selected time period. In order to perform rapid screening, the formulation can be kept at 40° C. for 2 weeks to 1 month, at which time stability is measured. In the case where the formulation will be stored at 2° C.-8° C., the formulation should generally be stable at 30° C. or 40° C. for at least 1 month and / or at 2° C.-8° C. for at least 2 years. In other embodiments, the stability of the protein formulation can be measured using a bioactivity assay.
[0131] The method of the present invention can be used in combination with other protein purification methods, such as affinity chromatography, hydroxyapatite chromatography, reversed phase liquid chromatography, ion exchange chromatography or any other commonly used protein purification technology. However, it is expected that the method of the present invention will eliminate or significantly reduce the need for other purification steps.
[0132] In a particular embodiment, the present invention relates to a method for purifying a protein from a solution, the method comprising:
[0133] (a) a first filtration step;
[0134] (b) a second filtration step;
[0135] (c) precipitation, washing and resuspension steps;
[0136] (d) an ultrafiltration / diafiltration (UF / DF) step; and
[0137] (e) optional formulation and final filtration steps,
[0138] Wherein the protein has a molecular weight (MW) between 5kDa-200kDa, preferably the protein has a MW between 10kDa and 150kDa, preferably between 12kDa and 100kDa, even more preferably between 12kDa and 45kDa, such as between 12kDa and 30kDa, such as about 12kDa to 15kDa, 24kDa-30kDa, 36kDa-45kDa or about 20kDa.
[0139] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first filtration step (a) comprises: (i) passing the solution through a first membrane, thereby producing a first permeate comprising the protein; and (ii) optionally, filtering the first permeate comprising the protein, preferably the first membrane having a pore size of a nominal molecular weight cut-off (NMWCO) of between 40 kDa and 100 kDa, preferably between 40 kDa and 80 kDa, even more preferably 50 kDa. It should be understood that in the first filtration step, the NMWCO of the first membrane is greater than the nominal molecular weight (NMW) of the protein to be purified.
[0140] When applied to the first filtration step, the solution containing the target protein is preferably 3-20 g / L cell broth, such as 4-15 g / L, or 5-12 g / L or 6-10 g / L, or 7 g / L or 8 g / L or 9 g / L cell broth.
[0141] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first membrane comprises regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic, polyether-sulfone, modified polyether-sulfone (mPES), polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF).
[0142] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the first filtration step is performed by tangential flow filtration (TFF) or by forward flow filtration (NFF), preferably TFF, preferably using purified water, preferably at a transmembrane pressure (TMP) of between 0.25-1.75 bar, such as 0.5-1.5 bar, 0.75-1.25 bar or about 1.0 bar, preferably comprising filtration between 2-4 diafiltration volumes (DV), such as 2 or 3 DV.
[0143] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100% of said protein is recovered in said first permeate.
[0144] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first permeate comprising the protein comprises 10%-100% less impurities than the solution, such as 20%-100% less, 30%-100% less, 40%-100% less, 50%-100% less, 60%-100% less, 70%-100% or even 80%-100% less impurities than the solution, such as 85% less impurities than the solution.
[0145] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein in the first permeate is purified between 10%-100%, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even between 80%-100%, compared to the solution.
[0146] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first permeate comprising the protein is preferably in the range of 1000 L to 2000 L first permeate volume / m 2 Between, such as 1500L / m 2 Filter through a 0.2 μm filter and optionally store at room temperature (RT) for up to 72 h.
[0147] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first filtration step (a) comprises: (i) passing the solution through a first membrane via TFF with 2DV at a TMP of about 1 bar using purified water, wherein the first membrane has a pore size of about 50 kDa NMWCO and is made of mPES; thereby producing a first permeate comprising the protein; and (ii) optionally, filtering the solution at a first permeate volume of about 1500 L / m 2 The first permeate containing the protein was filtered through a 0.2 μm filter.
[0148] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second filtration step (b) comprises: (i) concentrating the first permeate comprising the protein obtained at the end of step (a) using a second membrane, thereby producing a first retentate comprising the protein; and (ii) optionally, filtering the first retentate comprising the protein, preferably the second membrane having a pore size of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa nominal molecular weight cut-off (NMWCO). It should be understood that in the second filtration step, the NMWCO of the second membrane is less than the NMW of the protein to be purified.
[0149] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second membrane comprises regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic, polyether-sulfone, modified polyether-sulfone (mPES), polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF).
[0150] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second filtration step is carried out by TFF or by NFF, preferably TFF, preferably using purified water, preferably at a transmembrane pressure (TMP) of between 0.75-1.75 bar, such as 1.0-1.5 bar or about 1.25 bar.
[0151] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein in the first retentate is concentrated to a concentration between 50-200 mg / ml, such as 75-175 mg / ml or between 100-150 mg / ml, such as about 120-125 mg / ml.
[0152] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100% of said protein is recovered in said first retentate.
[0153] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the first retentate comprising the protein comprises 10%-100% less impurities than the first permeate comprising the protein, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even 80%-100% less impurities than the first permeate comprising the protein.
[0154] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the protein in the first retentate is purified between 10%-100%, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even between 80%-100% compared to the protein in the first permeate.
[0155] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein said first retentate comprising said protein is preferably concentrated to a concentration of 10-75 kg protein / m 215-50kg / m 2 Between, such as about 25kg / m 2 Filter through a 0.2 μm filter and optionally store at room temperature (RT) for up to 72 h.
[0156] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second filtration step (b) comprises: (i) concentrating the first permeate comprising the protein obtained at the end of step (a) to about 120-125 mg / ml with purified water via TFF at about 1.25 bar using a second membrane, wherein the second membrane has a pore size of about 10 kDa NMWCO and is made of mPES, thereby producing a first retentate comprising the protein; and (ii) optionally, filtering the first permeate at about 25 kg protein / m 2 The first retentate containing the protein was filtered through a 0.2 μm filter.
[0157] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the precipitation, washing and resuspension step (c) comprises:
[0158] (i) precipitating the protein in the first retentate obtained at the end of step (b) until a precipitate comprising the protein is formed;
[0159] (ii) washing the precipitate containing the protein;
[0160] (iii) resuspending the washed precipitate obtained at the end of step (c)(ii) to produce a second retentate comprising said protein;
[0161] (iv) optionally filtering the second retentate comprising the protein obtained at the end of step (c)(iii) through a third membrane, thereby producing a second permeate comprising the protein; and
[0162] (v) optionally, filtering the second permeate comprising the protein.
[0163] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the precipitation step (c)(i), and / or the washing step (c)(ii), and / or the resuspension step (c)(iii), and / or the filtration step (c)(iv) are implemented in a TFF device, preferably all steps (c)(i), (c)(ii), (c)(iii) and (c)(iv) are implemented in the same device, wherein the TFF device and the NFF device comprise the third membrane, preferably the third membrane comprises regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic, polyether-sulfone, mPES, polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF), more preferably the third membrane has a pore size between 0.05-0.35 μm, such as 0.1-0.3 μm or between 0.15-0.25 μm, such as 0.2 μm, preferably between 10-75 kg protein / m 2 15-50kg / m 2 Between, such as about 20 or 25kg / m 2 .
[0164] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the precipitation is carried out by a precipitation solution comprising a precipitant selected from the group consisting of a miscible solvent, a nonionic hydrophilic polymer, a multivalent metal ion such as Ca 2+ Mg 2+ , Mn 2+ or Fe 2+ and neutral salt, preferably a stabilizer, most preferably ((NH 4 ) + ) 2 (SO 4 ) 2- Preferably, the precipitate is in 1.4-2.2M, such as 1.6-2.0M, preferably about 1.8M ((NH 4 ) + ) 2 (SO 4 ) 2- Implemented below.
[0165] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein said precipitation is carried out by mixing the first retentate obtained at the end of step (b) comprising said protein with a solution until a precipitate is formed, preferably said solution is gradually added to said first retentate, more preferably said solution is mixed with said first retentate by stirring, more preferably said solution comprises between 2.8-3.4 M, such as 3.0-3.2 M, preferably about 3.1 M ((NH 4 )+ ) 2 (SO 4 ) 2- .
[0166] In one embodiment the invention relates to a method for purifying a protein from a solution as described herein, wherein the precipitate has a concentration between 20-80 mg / ml, such as 25-70 mg / ml or between 30-60 mg / ml, such as about 50 mg / ml.
[0167] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein washing the precipitate containing the protein in step (c)(ii) comprises replacing the precipitating solution with a washing solution, and preferably washing the precipitate with 2-8 DV, such as 4-6 DV or 5 DV of the washing solution.
[0168] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the washing step (c)(ii) is carried out at a transmembrane pressure (TMP) of between 0.1-1.5 bar, such as 0.2-1.0 bar, 0.3-0.75 bar or about 0.5 bar.
[0169] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the washing solution comprises a precipitant at a concentration between 1.4-2.2 M, such as 1.6-2.0 M, preferably about 1.8 M, preferably the precipitant is ((NH 4 ) + ) 2 (SO 4 ) 2- More preferably, the washing solution is 1.8 M ((NH 4 ) + ) 2 (SO 4 ) 2- .
[0170] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the washed precipitate obtained at the end of step (c)(ii) is resuspended in a resuspension solution comprising a precipitant at a concentration between 0.8-0.4 M, such as 0.7-0.5 M, preferably about 0.6 M, preferably the precipitant is ((NH 4 ) + ) 2 (SO 4 ) 2- More preferably, the resuspension solution is 0.6 M ((NH 4 ) + )2 (SO 4 ) 2- .
[0171] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100% of said protein is recovered in said second permeate.
[0172] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second permeate comprising the protein comprises 10%-100% less impurities than the first retentate, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even 80%-100% less impurities than the first retentate.
[0173] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the protein in the second permeate is purified between 10%-100%, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even between 80%-100% compared to the first retentate.
[0174] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the precipitation, washing and resuspending step (c) is carried out in a culture medium comprising a pore size of about 20-25 kg / m 2 The method is implemented in a TFF device with a third membrane, wherein the third membrane comprises mPES, and the method comprises:
[0175] (i) precipitating the protein in the first retentate obtained at the end of step (b) until a precipitate comprising the protein is formed; wherein the precipitate is prepared by mixing the first retentate comprising the protein obtained at the end of step (b) with 3.1 M ((NH 4 ) + ) 2 (SO 4 ) 2- Mixing until a precipitate is formed, wherein the ((NH 4 ) + ) 2 (SO 4 ) 2- Gradually add to the first retentate and mix with the first retentate by stirring until about 1.8 M ((NH 4 )+ ) 2 (SO 4 ) 2- and a final concentration of 50 mg / ml protein;
[0176] (ii) at a TMP of about 0.5 bar with a mixture containing about 1.8 M ((NH 4 ) + ) 2 (SO 4 ) 2- washing the precipitate containing the protein with a 5DV washing solution;
[0177] (iii) Add purified water to a final concentration of approximately 0.6 M ((NH 4 ) + ) 2 (SO 4 ) 2- (resuspending solution) to resuspend the washed precipitate obtained at the end of step (c)(ii), thereby producing a second retentate comprising the protein; and
[0178] (iv) optionally filtering the second retentate comprising the protein obtained at the end of step (c)(iii) through the third membrane, thereby producing a second permeate comprising the protein.
[0179] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the (d) ultrafiltration / diafiltration (UF / DF) step comprises:
[0180] (i) diafiltering the second permeate comprising the protein obtained at the end of step (c), thereby producing a first diafiltrate comprising the protein;
[0181] (ii) concentrating the first diafiltrate comprising said protein obtained at the end of step (d)(i) to thereby produce a third retentate comprising said protein;
[0182] (iii) diafiltering the third retentate of step (d)(ii) comprising the protein, thereby producing a second diafiltrate comprising the protein;
[0183] (iv) optionally, filtering the second diafiltrate comprising the protein.
[0184] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the diafiltration step (d)(i), and / or the concentration step (d)(ii), and / or the diafiltration step (d)(iii) are performed in a TFF device, preferably all steps (d)(i), (d)(ii) and (d)(iii) are performed in the same device, wherein the TFF device and the NFF device comprise a fourth (UF) membrane, preferably the diafiltration step (d)(i), and / or the concentration step (d)(ii), and / or the diafiltration step (d)(iii) is between 0.75 and 1.75 bar. , such as 1.0-1.5 bar or about 1.2 bar transmembrane pressure (TMP) is preferably implemented with a main buffer, such as phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer, preferably the pH of the main buffer is about 5 to about 7.5, about 5.5 to about 7.2, such as pH is about 5, 5.5, 5.8-6.1, 6, 6.1, 6.5 or 7, preferably the concentration of the main buffer is about 5mM to about 50mM, about 5mM to about 40mM, about 5mM to about 30mM, about 10mM to about 20mM, or about 10mM, about 20mM or about 30mM. In other embodiments, the buffer in the formulation is Tris buffer present at a concentration of less than about 5 mM to about 50 mM, about 5 mM to about 40 mM, about 5 mM to about 30 mM, about 10 mM to about 20 mM, or about 10 mM, about 20 mM, or about 30 mM, more preferably the primary buffer is 20 mM citrate buffer pH 6.0.
[0185] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the fourth (UF) membrane comprises regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic, polyether-sulfone, polyarylsulfone, polysulfone, mPES, polyimide, polyamide, polyvinylidene fluoride (PVDF), more preferably the fourth (UF) membrane has a pore size of a nominal molecular weight cut-off (NMWCO) of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa. It should be understood that in the UF / DF step, the NMWCO of the fourth (UF) membrane is less than the NMW of the protein to be purified.
[0186] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second permeate obtained at the end of step (c) comprising the protein is diafiltered, preferably with a main buffer, with between 1-4 diafiltration volumes (DV), such as 1 DV.
[0187] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein said concentration step (d)(ii) comprises concentrating said first diafiltrate comprising said protein obtained at the end of step (d)(i) into a third retentate comprising said protein in said main buffer at a concentration of between 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml.
[0188] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the third retentate obtained at the end of step (d)(ii) comprising said protein is preferably diafiltered with said main buffer with 1-8 diafiltration volumes (DV), such as 3-6, or 4 DV or 5 DV.
[0189] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100%, preferably more than 90%, such as more than 95% of said protein is recovered in said second diafiltrate compared to a third retentate comprising said protein.
[0190] In one embodiment, the present invention relates to a method for purifying a protein from a solution as described herein, wherein the second diafiltrate comprising the protein is preferably heated at 10-75 kg / m 2 Between, such as 15-60kg / m 2 , 20-50kg / m 2 , or about 30kg / m 2 or 40kg / m 2 Filter through a 0.2 μm filter and optionally store at room temperature (RT) for up to 72 h.
[0191] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the UF / DF step (d) is carried out at a TMP of about 1.2 bar with a main buffer in a TFF apparatus comprising a fourth (UF) membrane having a NMWCO of about 10 KDa, the fourth (UF) membrane comprising mPES,
[0192] (i) diafiltrating the second permeate comprising the protein obtained at the end of step (c) with 1 DV of main buffer, thereby producing a first diafiltrate comprising the protein;
[0193] (ii) concentrating the first diafiltrate comprising the protein obtained at the end of step (d)(i) until it is about 50-55 mg / ml in the main buffer, thereby producing a third retentate comprising the protein;
[0194] (iii) diafiltering the third retentate of step (d)(ii) comprising the protein with 4 or 5 DV main buffer to produce a second diafiltrate comprising the protein; and
[0195] (iv) Optionally, at about 30-40 kg / m 2 The second diafiltrate containing the protein was filtered through a 0.2 μm filter.
[0196] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the formulation and final filtration step (e) comprises:
[0197] (i) formulating the second diafiltrate obtained at the end of step (d) comprising the protein, thereby producing a protein formulation; and
[0198] (ii) optionally filtering the protein formulation.
[0199] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein said formulating step (e)(i) comprises adding an excipient to said second diafiltrate comprising said protein.
[0200] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the excipient is selected from the group consisting of a lyoprotectant, a surfactant, a filler, a tonicity adjuster, a stabilizer and a preservative.
[0201] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein formulation comprises
[0202] - protein at a concentration of 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml protein;
[0203] - a primary buffer, such as phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer, preferably the pH of the primary buffer is about 5 to about 7.5, preferably the concentration of the primary buffer is about 5 mM to about 50 mM, more preferably the primary buffer is 20 mM citrate, pH 6.0; and
[0204] -optionally from about 1% to 12% of a stabilizer selected from sucrose, sorbitol, mannitol, glycine, inositol, sodium chloride, methionine, arginine and arginine hydrochloride, preferably mannitol, preferably 10 mg / ml; and
[0205] -Optionally a surfactant at a concentration of about 0.001% to 0.6% selected from polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleate.
[0206] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein formulation is preferably concentrated at 10-75 kg / m 2 Between, such as 15-60kg / m 2 , 20-50kg / m 2 , or about 30kg / m 2 or 40kg / m 2 Filter through a 0.2 μm filter.
[0207] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein formulation is stable and can be stored at room temperature (RT) for up to 168 h or at -20°C for up to 2 y or even longer.
[0208] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein formulation is administered to a patient.
[0209] In certain embodiments, the protein formulation is administered to a subject by injection (eg, subcutaneously, intravascularly, intramuscularly, or intraperitoneally), by inhalation, orally, or rectally.
[0210] In one embodiment, the invention relates to a method for purifying a protein from a solution as described herein, wherein the protein formulation is lyophilized.
[0211] In one embodiment, the invention relates to a kit comprising a protein formulation of the invention and optionally instructions for use.
[0212] The following examples illustrate specific embodiments of the disclosed methods and various uses thereof. They are presented for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
[0213] 6. Embodiment
[0214] The goal was to develop an alternative and robust purification method for recombinantly expressed and secreted Nanobodies that reduces CoG compared to standard methods while maintaining sufficient quality. Another goal was the scalability of the method.
[0215] 6.1 Materials and Methods
[0216] For all tangential flow filtration (TFF) steps, a 1.5-well plate from Sartorius was used. SMART system (2L fermenter equivalent) and Pump equipment (10L and 100L fermenter equivalent).
[0217] Unless otherwise stated, all steps were performed at room temperature (RT).
[0218] All analyses were performed in-house using routine methods known to those skilled in the art, including:
[0219] -OD280 measurement: The OD280 was measured by using a NanoDrop ND-1000 spectrophotometer (NanoDrop TM The protein concentration was determined by measuring the absorbance at 280 nm.
[0220] - DNA measurement via qPCR-based assay to detect and quantify residual host cell DNA in purified samples.
[0221] -SE-HPLC: Determination of ALX- by size exclusion high performance liquid chromatography purity.
[0222] -PA-HPLC: Determination of ALX- concentration.
[0223] 6.2 Starting Materials
[0224] The starting material was cell broth containing ALX nanobodies expressed and secreted by Pichia pastoris essentially as described elsewhere (Joosten et al., 2003 Microb Cell Fact. 30:1; Rahbarizadeh et al. 2006 Mol Immunol. 43:426-435). The target final concentration was 9 g / L cell broth (measured by PA-HPLC). ALX nanobodies are monovalent polypeptides containing one VHH and having a molecular weight of 13.4 kDa (non-reducing conditions).
[0225] 6.3 First filtration step (clarification)
[0226] The purpose of the first filtration step (diafiltration) is to separate the Pichia pastoris host cells from the secreted target product and to reduce the levels of process-related impurities such as host cell proteins (HCPs), DNA and color as well as product-related variants such as high molecular weight (HMW) contaminants (clarification).
[0227] The Sartoflow SMART system (2 L fermenter equivalent) and SartoJet pump equipment (10 L and 100 L fermenter equivalent) from Sartorius were used. The TFF membrane was an mPES hollow fiber filter module (Spectrum Labs) with a pore size of 50 kDa NMWCO. Purified water was used for the first filtration step without any pH adjustment or conductivity adjustment of the starting material.
[0228] After filling the membrane with purified water and subsequently cell broth, the permeate valve was opened and the transmembrane pressure (TMP) was adjusted to 1 bar.The first filtration step was performed with 2 DV (diafiltration volume) of purified water.
[0229] Routinely, more than 80% of the product was recovered in the (first) permeate as measured by PA-HPLC.
[0230] If you want to store ALX nanobody, use 0.45 / 0.2μm A filtration step was performed using a 2 filter (Sartorius). After this filtration step, the filtrate was stored at room temperature for up to 72 h.
[0231] 6.4 Second Filtration Step (Concentration Step)
[0232] The purpose of the second filtration step (ultrafiltration) is twofold. First, this step is used to concentrate the permeate to 120 + Target concentration of 10 mg / ml. Secondly, this step is used to reduce the amount of various small impurities.
[0233] A Sartoflow SMART system (2 L fermenter equivalent) and a SartoJet pump unit (10 L and 100 L fermenter equivalent) from Sartorius were operated. For the second filtration step, the TFF membrane was a hollow fiber filter module with a pore size of 10 kDa. ( Slice box; Sartorius Stedim). Purified water was also used for the second filtration step, and no pH adjustment or conductivity adjustment of the starting material was performed. The loading amount was 0.7-1 kg ALX nanobody / m 2 Membrane surface area.
[0234] After filling the membrane with water and then the first permeate, the permeate valve was opened and the TMP was adjusted to 1.25 bar. + At a concentration of 10 mg / ml (total protein), the first retentate containing ALX Nanobody was collected.
[0235] Typically, 100% of the product was recovered in the first retentate as measured by PA-HPLC.
[0236] If the ALX Nanobody is to be stored, a filtration step is performed using a 0.45 / 0.2 μm Sartopore 2 filter (Sartorius). After this filtration step, the filtrate is stored at room temperature for up to 72 h.
[0237] 6.5 Precipitation, washing and resuspension steps
[0238] The purpose of the precipitation, washing and resuspension steps is to precipitate the ALX Nanobody and wash the precipitate, thereby maintaining the ALX- The precipitate was removed, while process-related impurities (e.g., components derived from cell walls) were resuspended and reduced by filtration through a membrane with a pore size of 0.2 μm. Notably, the precipitate was unable to pass through the membrane. Next, the ALX Nanobody was resuspended by dilution with purified water, after which the soluble ALX Nanobody was filtered through the membrane, while retaining any remaining solid impurities.
[0239] The precipitation, washing and resuspension steps were all performed in a Sartoflow SMART system (2 L fermenter equivalent) and a SartoJet pump unit (10 L or 4*10 L fermenter equivalent) from Sartorius.
[0240] By adding 3.1 M ammonium sulfate (NH 4 ) 2 SO 4 ) stock solution for precipitation, aiming for a final concentration of 1.8 M ammonium sulfate and a protein concentration of approximately 50 mg / mL. 3.1 M ammonium sulfate stock solution was gradually added with gentle stirring at room temperature until a precipitate formed.
[0241] After precipitation, the precipitate was stored at room temperature for 2 h up to 24 h.
[0242] The ALX nanobody was prepared using a TFF membrane (i.e., a cassette filter module (Hydrosart) with a pore size of 0.2 μm) (Sartocon Slice cassette; Sartorius Stedim) and 0.6-0.8 kg ALX nanobody / m 2 The loading volume of membrane surface area was subjected to washing steps.
[0243] Diafiltration was performed with 5 DV of 1.8 M ammonium sulfate.
[0244] Purified water was added to reach a final concentration of 0.6 M ammonium sulfate in order to resuspend the ALX Nanobody precipitate (second retentate).The second retentate containing the resuspended soluble ALX Nanobody was then filtered through a membrane (pore size 0.2 μm) to produce a second permeate.
[0245] Typically, greater than 75%-80% of the protein was recovered after precipitation, washing, resuspension and filtration (second permeate) as measured by PA-HPLC.
[0246] When no immediate processing was planned, a 0.6 M ammonium sulfate second permeate sample was filtered through a 0.45 / 0.2 μm Sartopore 2 filter (Sartorius). After this filtration step, the filtrate was stored at room temperature for up to 72 h.
[0247] 6.6 Ultrafiltration / diafiltration (UF / DF) steps
[0248] The purpose of the UF / DF step is to concentrate the product and exchange the 0.6 M ammonium sulfate buffer into the main buffer.
[0249] The UF / DF step was performed on the Sartoflow SMART system (2L fermenter equivalent) and SartoJet pump equipment (10L and 100L fermenter equivalent) from Sartorius as described above. The TFF membrane was a cassette filter module (Sartocon Slice cassette, from Sartorius Stedim) with a cut-off point of 10 kDa (HydroSart). The main buffer was 20 mM citrate pH 6.0.
[0250] After filling the membrane with water and the second permeate of step 6.5, the permeate valve was opened and the transmembrane pressure (TMP) was adjusted to 1.2 bar. The first DF step (first diafiltrate containing ALX Nanobody) was performed with 1 DV of main buffer. Next, the UF step was completed until the ALX Nanobody reached a concentration of 55 mg / ml (third retentate). Subsequently, the second DF step (second diafiltrate containing ALX Nanobody) was performed with 4 DV of main buffer.
[0251] Routinely, greater than 98% of the ALX Nanobody was recovered at concentrations of at least 50 mg / ml as measured by PA-HPLC.
[0252] If the ALX Nanobody is to be stored, a filtration step is performed using a 0.45 / 0.2 μm Sartopore 2 filter (Sartorius). After this filtration step, the filtrate is stored at room temperature for up to 72 h.
[0253] 6.7 Formulation and final filtration steps
[0254] A general and simplified purification method is described above, requiring only precipitation and filtration steps, which are all performed in the same instrument. The final product is a purified protein in the main buffer, but without any other excipient or excipients.
[0255] However, the final formulation may require excipients, which may or may not have an impact on the UF / DF step, for various reasons, such as storage, ease of administration, lyophilization, etc. Although the formulation and final filtration steps are not explicitly part of the purification method of the present invention, the addition of a separate formulation step in the purification method of the present invention contributes to the versatility of the aforementioned purification process method on the one hand, and provides the possibility to adjust the final formulation on the other hand.
[0256] In this case, 50 mg / ml of ALX Nanobody in 20 mM citrate buffer (pH 6.0) was diluted with 16.6 mg / ml mannitol in 20 mM citrate buffer (pH 6.0) at room temperature with continuous stirring until 20 mg / ml ALX Nanobody was obtained.
[0257] A 0.45 / 0.2 μm sterile filtration step was performed on Sartopore 2 filters (Sartorius) under standard conditions. Bulk purified liquid ALX Nanobody was stored at ≤-20°C. In addition, it was shown that purified liquid ALX Nanobody could be stored at room temperature for more than 168 h after filtration without loss of activity.
[0258] Routinely, greater than 96% of the product was recovered as measured by PA-HPLC.
[0259] 6.8 Conclusions of DSP without Chromatography Case Study
[0260] Above is a general and simplified purification procedure described, which results in a final process recovery of at least 62% compared to the starting amount of protein in solution, and the product quality is comparable to the conventional DSP method using a chromatography step. Only the HCP content is slightly higher, but within the acceptable standards for various uses.
[0261] 6.9 Scalability (MIP operation)
[0262] The above purification method was performed at 10 L scale. In order to evaluate the scalability of the purification method and ensure efficient and successful transfer to CMO, a Man-in-Plant (MIP) run at 100 L fermentation scale was performed. In addition, a 2000 L run was performed.
[0263] Essentially, the purification method described above was repeated, but on a larger scale.
[0264] 6.9.1 Starting materials
[0265] The starting material for clarification was approximately 109 L of cell broth containing ALX Nanobodies expressed and secreted by Pichia pastoris in minimal medium. The final concentration in the fermenter was 9.1 g / L cell broth (11.9 g / L, cell-free) (measured by PA-HPLC method).
[0266] No pH or conductivity adjustments were made to the starting materials.
[0267] 6.9.2 First Filtration Step
[0268] The first filtration step was as described above, but now the hollow fiber used for the clarification step of the MIP run was a 65 cm filter height from SpectrumLabs with a surface area of 5100 cm 2 MiniKros membrane NO6-EO50-10-N.
[0269] To evaluate the effectiveness of diafiltration volume, two modes were tested using (i) 2DV, as described previously; and (ii) 3DV.
[0270] The results of both 2DV and 3DV are basically the same.
[0271] 6.9.3 Second Filtration Step
[0272] The second filtration step is substantially as described above, including the filter used.
[0273] 6.9.4 Precipitation, washing and resuspension steps
[0274] The precipitation, washing and resuspension steps were essentially as described above, including the filters used.
[0275] 6.9.5 UF / DF steps
[0276] The UF / DF step was essentially as described above, including the filters used. The concentration of ALX Nanobody obtained was 52 mg / mL.
[0277] 6.9.6 Preparation and final filtration steps
[0278] The formulation procedure was performed essentially as described above, but using a stock concentration of 16.3 mg / ml mannitol to achieve a final concentration of 10 mg / mL mannitol.
[0279] 6.10 Quality Analysis
[0280] The purified liquid ALX- The concentration ("second percolate") was 19.4 mg / mL. The recoveries of the different process steps ranged from 77% to 100%, resulting in an overall process recovery of 63%.
[0281] 6.10.1 RP-UHPLC
[0282] RP-UHPLC was used to characterize intermediate and final samples obtained from the MIP run. This method has been qualified as a limit test for product-related variants, unpaired cysteine variants, and one or more carbamylated variants, if present. The relative amounts of deleted SS variants and carbamylated variants were determined by measuring the post-peak surface area of each peak eluted from the RP-UHPLC column relative to the post-peak surface area of the total surface (expressed as %).
[0283] Reverse phase ultra-high performance liquid chromatography (RP-UHPLC) analysis showed that the purified liquid ALX Nanobody contained 0.6% of the deleted SS variant and 1.8% of the carbamylated variant.
[0284] 6.10.2SE-HPLC
[0285] SE-HPLC was used to monitor the levels of high molecular weight (HMW) species of ALX nanobodies at different intermediate steps of the purification process and in the final product ( Figure 1 In addition, intact ALX nanobody (main peak) and low molecular weight (LMW, proteolytically degraded, appearing as a later peak) can also be detected.
[0286] SE-HPLC analysis of intermediate and final samples from the MIP run showed that the HMW species (% pre-peak) decreased during the purification process from 5.1% in the filtered 10 kD ultrafiltration retentate to 3.1% in the purified final liquid ALX Nanobody. An overlay of the different SE-HPLC analyses of the different samples from the MIP run is shown in Figure 1 middle.
[0287] 6.10.3 CE-IEF product analysis
[0288] Different intermediate samples from the MIP run and the purified final liquid ALX Nanobody were analyzed via capillary electrophoresis isoelectric focusing (CE-IEF) to determine the levels of product-associated variants such as acidic and basic variants.
[0289] CE-IEF analysis of intermediate samples of the MIP run showed that the percentage of acidic variants decreased during the purification process. The percentage of basic variants was already low (1%-1.2%) and showed only limited clearance (0.6%). On the other hand, in the purified liquid ALX Nanobody, the percentage of acidic variants decreased from 19.8%-22.7% to 3.4%.
[0290] 6.10.4 Potency Analysis
[0291] The potency of the purified liquid ALX Nanobodies run by MIP was evaluated in a qualified cell-based functional potency assay.
[0292] The purified final liquid ALX Nanobody had a relative potency of 108%.
[0293] 6.10.5 Purity determination by reduction of CGE
[0294] The purity of different intermediate samples from the MIP run and the purified final liquid ALX Nanobody sample was analyzed via capillary gel electrophoresis (CGE).This method tests for the presence of charged product-associated variants.
[0295] A summary of the CGE integration data (% main peak) for the different samples is given in Table 1.
[0296] Table 1: Reduced CGE analysis of different samples from the MIP run.
[0297]
[0298]
[0299] 6.11 General conclusions
[0300] The results obtained with this purification method (10L, 100L and 2000L fermentation scale) demonstrated its robustness (notably, the method has been repeated multiple times with essentially identical results). Based on these results, the method was locked and deemed suitable for GMP-compliant drug substance (DS) manufacturing.
[0301] The described purification method resulted in a downstream process recovery range of 63% and reduced process-related impurities (eg, HCPs, mannans, DNA, color) as well as product-related variants (eg, HMW species).
[0302] In Table 2, a comparison of protein quality using a standard conventional downstream process (DSP) purification method including chromatography and a chromatography-free DSP purification method of the present invention is provided.
[0303] The purification method of the present invention has been extensively tested for monovalent nanobodies (molecular weight between 12-15 kDa), but can also be used for bivalent nanobodies (molecular weight included between 24-30 kDa) and trivalent nanobodies (molecular weight included between 36-45 kDa). Similar conditions to monovalent nanobodies can be used for bivalent and trivalent nanobodies. Nevertheless, if it is considered necessary, it is standard practice to further optimize the adjustment of the method of the present invention for bivalent and trivalent nanobodies.
[0304] Compared with conventional chromatography methods, the method of the present invention has higher process recovery and significantly lower commodity costs. When conventional DSP was compared with the purification method of the present invention at a 100 L scale, an 86% reduction in cost was achieved while the quality was adequate.
[0305] Table 2: Comparison of conventional purification methods and purification methods without chromatography
[0306]
[0307]
Claims
1. A method for purifying a protein from a solution, the protein being a polypeptide comprising an immunoglobulin single variable domain (ISVD), the solution being obtained by expressing the protein in a host or a host cell, the method comprising: (a) a first filtering step, comprising: (i) passing the solution through a first membrane, thereby producing a first permeate comprising the protein, wherein the first membrane has a pore size of a nominal molecular weight cut-off (NMWCO) between 40 kDa and 100 kDa, preferably between 40 kDa and 80 kDa, even more preferably 50 kDa; and wherein the nominal molecular weight cut-off of the first membrane is greater than the nominal molecular weight of the protein; (b) a second filtration step, comprising: (i) concentrating said first permeate obtained at the end of step (a) using a second membrane, thereby producing a first retentate comprising said protein, wherein the second membrane has a pore size of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa NMWCO; and wherein the second membrane has a nominal molecular weight cut-off that is less than the nominal molecular weight of the protein to be purified; (c) a precipitation, washing and resuspension step comprising: (i) precipitating the first retentate comprising the protein obtained at the end of step (b) until a precipitate comprising the protein is formed; (ii) washing the precipitate comprising the protein using a third membrane; (iii) resuspending the washed precipitate obtained at the end of step (c)(ii) to produce a second retentate comprising said protein; (iv) filtering said second retentate comprising said protein obtained at the end of step (c)(iii) through said third membrane, thereby producing a second permeate comprising said protein, wherein the third membrane has a pore size between 0.05-0.35 μm, such as 0.1-0.3 μm or between 0.15-0.25 μm, such as 0.2 μm; (d) an ultrafiltration / diafiltration (UF / DF) step comprising: (i) diafiltrating the second permeate comprising the protein obtained at the end of step (c) using a fourth membrane, thereby producing a first diafiltrate comprising the protein, wherein the fourth membrane has a pore size of between 2 kDa and 50 kDa, such as between 4 kDa and 40 kDa, between 6 kDa and 30 kDa, between 8 kDa and 20 kDa, more preferably 10 kDa or 15 kDa NMWCO; and wherein the fourth membrane has a nominal molecular weight cut-off that is less than the nominal molecular weight of the protein to be purified; (ii) concentrating said first diafiltrate comprising said protein obtained at the end of step (d)(i) using said fourth membrane, thereby producing a third retentate comprising said protein; (iii) diafiltrating the third retentate of step (d)(ii) comprising the protein using the fourth membrane to produce a second diafiltrate comprising the protein; (e) an optional formulation and final filtration step comprising: (i) formulating the second diafiltrate obtained at the end of step (d) comprising the protein in a formulation buffer, thereby producing a formulated product comprising the protein; and (ii) optionally filtering the formulated product; Wherein the protein has a molecular weight (MW) between 5kDa-200kDa, preferably the protein has a MW between 10kDa and 150kDa, preferably between 15kDa and 100kDa, even more preferably between 15kDa and 50kDa, such as between 15kDa-30kDa, such as about 20kDa.
2. The method for purifying a protein from a solution according to claim 1, wherein the first filtration step (a), the second filtration step (b), the precipitation step (c)(i), the washing step (c)(ii), the resuspension step (c)(iii), the filtration step (c)(iv), the diafiltration step (d)(i), the concentration step (d)(ii) and the diafiltration step (d)(iii) are carried out by tangential flow filtration (TFF), preferably all steps (a), (b), (c)(i), (c)(ii), (c)(iii), (c)(iv), (d)(i), (d)(ii) and (d)(iii) are carried out in the same device.
3. The method for purifying a protein from a solution according to claim 1 or 2, wherein the first membrane, and / or the second membrane, and / or the third membrane, and / or the fourth membrane comprises modified polyether-sulfone (mPES), regenerated cellulose, polypropylene, cellulose acetate, polylactic acid, ceramic polyether-sulfone, polyarylsulfone, polysulfone, polyimide, polyamide, polyvinylidene fluoride (PVDF).
4. A method for purifying a protein from a solution according to any one of claims 1 to 3, wherein the first filtration step (a) comprises filtering with 2-4 diafiltration volumes (DV), such as 3 DV, of purified water.
5. A method for purifying a protein from a solution according to any one of claims 1 to 4, wherein between 50%-100%, such as between 60%-100%, or even between 80%-100% of the protein is recovered in the first permeate.
6. A method for purifying a protein from a solution according to any one of claims 1 to 5, wherein the first permeate comprising the protein comprises 10%-100% less impurities than the solution, such as 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, or even 80%-100% less impurities than the solution.
7. A method for purifying a protein from a solution according to any one of claims 1 to 6, wherein the second filtration step (b) comprises using purified water.
8. A method for purifying a protein from a solution according to any one of claims 1 to 7, wherein the protein in the first retentate is concentrated to a concentration between 50-200 mg / ml, such as 75-175 mg / ml or between 100-150 mg / ml, such as about 120 mg / ml or 125 mg / ml.
9. A method for purifying a protein from a solution according to any one of claims 1 to 8, wherein the precipitation is carried out by a precipitation solution comprising a precipitant selected from the group consisting of a miscible solvent, a nonionic hydrophilic polymer, a polyvalent metal ion such as Ca 2+ Mg 2+ , Mn 2+ or Fe 2+ and neutral salt, preferably a stabilizer, most preferably ((NH4) + )2(SO4) 2- .
10. A method for purifying a protein from a solution according to claim 9, wherein the precipitate is prepared with 1.4-2.2 M, such as 1.6-2.0 M, preferably about 1.8 M ((NH4) + )2(SO4) 2- Implementation.
11. A method for purifying a protein from a solution according to any one of claims 9 to 10, wherein the washing of the precipitate containing the protein in step (c)(ii) comprises replacing the precipitating solution with a washing solution, and preferably washing the precipitate with 2-8 DV, such as 4-6 DV or 5 DV of the washing solution, preferably the washing solution comprises a precipitant having a concentration between 1.4-2.2 M, such as 1.6-2.0 M, preferably about 1.8 M, preferably the precipitant is ((NH4) + )2(SO4) 2- .
12. A method for purifying a protein from a solution according to any one of claims 1 to 11, wherein the washed precipitate obtained at the end of step (c)(ii) is resuspended in a resuspension solution comprising a precipitant at a concentration between 0.8 and 0.4 M, such as 0.7 and 0.5 M, preferably about 0.6 M, preferably the precipitant is ((NH4) + )2(SO4) 2- .
13. Process for purifying a protein from a solution according to any one of claims 1 to 12, wherein the second permeate obtained at the end of step (c) comprising the protein is diafiltered using between 1 and 4 diafiltration volumes (DV), such as 1 DV, of the main buffer.
14. A method for purifying a protein from a solution according to any one of claims 1 to 13, wherein the concentration of the protein in the third retentate is between 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml.
15. A process for purifying a protein from a solution according to any one of claims 1 to 14, wherein the third retentate comprising the protein obtained at the end of step (d)(ii) is diafiltered with 1-8 diafiltration volumes (DV), such as 3-6, or 4 DV or 5 DV of main buffer.
16. A method for purifying a protein from a solution according to any one of claims 1 to 15, wherein the formulated product comprises - protein at a concentration of 10-100 mg / ml, such as 25-80 mg / ml or between 40-60 mg / ml, such as about 50 mg / ml or 55 mg / ml protein; - a primary buffer, such as phosphate buffer, Tris buffer, acetate buffer, histidine buffer, HEPES buffer, preferably the pH of the primary buffer is about 5 to about 7.5, preferably the concentration of the primary buffer is about 5 mM to about 50 mM, more preferably the primary buffer is 20 mM citrate, pH 6.0; and -optionally about 1% to 12% of a stabilizer selected from sucrose, sorbitol, mannitol, glycine, inositol, sodium chloride, methionine, arginine and arginine hydrochloride, preferably mannitol, preferably 10 mg / ml; and -Optionally a surfactant selected from polysorbates at a concentration of about 0.001% to 0.6% -20, Polysorbate 40, Polysorbate 60, Polysorbate 65, Polysorbate 80, Polysorbate 85, Poloxamer 188, Sorbitan monolaurate, Sorbitan monopalmitate, Sorbitan monostearate, Sorbitan monooleate, Sorbitan trilaurate, Sorbitan tristearate, Sorbitan trioleate.
Citation Information
Patent Citations
Process for producing fusion proteins comprising scfv fragments by a transformed mould
WO1994029457A2
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1996034103A1
Compositions and methods for regulating lymphocyte activation
WO1999042077A2
Dual-specific ligand and its use
WO2003002609A2
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2
